Who are the top shareholders of the Gufic BioScience?

The top shareholders of Gufic BioScience include promoter Jayesh Pannalal Choksi with 24.62%, public shareholder Motilal Oswal Financial Services Ltd at 3.32%, mutual funds with 3.39%, 21 Foreign Institutional Investors holding 0.31%, and individual investors collectively owning 15.15%.

The top shareholders of Gufic BioScience include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jayesh Pannalal Choksi, owning 24.62% of the company. Additionally, Motilal Oswal Financial Services Ltd is the highest public shareholder, holding 3.32%. The company also has mutual funds involved through five schemes, which collectively hold 3.39%, and 21 Foreign Institutional Investors (FIIs) that hold 0.31%. Individual investors collectively own 15.15% of the shares.

Who are in the management team of Gufic BioScience?

As of March 2022, Gufic BioScience's management team includes Jayesh P Choksi (Chairman & Managing Director), Pranav J Choksi (Whole Time Director & CEO), and other directors such as Pankaj Gandhi and Dilip Ghosh. The board also features several non-executive and independent directors.

As of March 2022, the management team of Gufic BioScience includes the following individuals:<BR><BR>1. Jayesh P Choksi - Chairman & Managing Director<BR>2. Pranav J Choksi - Whole Time Director & CEO<BR>3. Pankaj Gandhi - Whole-time Director<BR>4. Dilip Ghosh - Whole-time Director<BR>5. Ami Naresh Shah - Company Secretary & Compliance Officer<BR><BR>Additionally, there are several non-executive and independent directors on the board, including:<BR>- Shreyas Patel<BR>- Gopal Daptari<BR>- Shrirang V Vadiya<BR>- Rabi Narayan Sahoo<BR>- Anusanjiv Aurora<BR><BR>Lastly, Balram Singh serves as a Non-Executive & Non-Independent Director.

What does Gufic BioScience do?

Gufic BioSciences Ltd manufactures and markets active pharmaceutical ingredients and generic pharmaceuticals, with a market cap of Rs 3,693 Cr. As of March 2025, it reported net sales of 205 Cr and a net profit of 8 Cr.

Overview: <BR>Gufic BioSciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients and generic pharmaceuticals within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History: <BR>Gufic BioSciences was incorporated in July 1984 and underwent a reverse merger with Central Finance. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 205 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 8 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 3,693 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 53.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.03% <BR>Debt-Equity: 0.57 <BR>Return on Equity: 13.13% <BR>Price to Book: 6.97<BR><BR>Contact Details: <BR>Address: Shop-37 1st Flr Kamala Bhavan, Swami Nityanand Road Andheri(E Mumbai Maharashtra : 400069 <BR>Tel: 91-022-66919187/67261007/66919189 <BR>Email: info@guficbio.com <BR>Website: http://www.gufic.com

Has Gufic BioScience declared dividend?

Yes, Gufic BioSciences Ltd has declared a 10% dividend, amounting to 0.1 per share, with an ex-date of September 17, 2024. The dividend yield is 0.03%, and while the company has shown significant long-term growth, it experienced a recent decline in price returns over the last six months.

Gufic BioSciences Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.1<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.03%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.6%, with a dividend return of 0%, resulting in a total return of -16.6%.<BR><BR>Over the past year, the price return was 18.87%, the dividend return was 0.03%, leading to a total return of 18.9%.<BR><BR>In the two-year period, the price return was 89.23%, with a dividend return of 0.08%, giving a total return of 89.31%.<BR><BR>For the three-year period, the price return was 66.49%, the dividend return was 0.14%, resulting in a total return of 66.63%.<BR><BR>In the four-year timeframe, the price return was 94.44%, with a dividend return of 0.22%, culminating in a total return of 94.66%.<BR><BR>Finally, over five years, the price return was 479.22%, with a dividend return of 0.58%, resulting in a total return of 479.8%.<BR><BR>Overall, Gufic BioSciences has declared a dividend while experiencing varying total returns across different periods, with significant growth over the long term despite a recent decline in the short term. The dividend yield remains low, indicating that the company may be reinvesting profits for growth rather than distributing them as dividends.

Who are the peers of the Gufic BioScience?

Gufic BioScience's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, RPG LifeScience, Morepen Labs, Advanced Enzyme, and Guj. Themis Bio. Gufic BioScience has average management risk and growth, with a 1-year return of 16.75%.

Peers: The peers of Gufic BioScience are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, RPG LifeScience., Morepen Labs., Advanced Enzyme, Guj. Themis Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, RPG LifeScience., Advanced Enzyme, and Guj. Themis Bio., while Good management risk is found at Divi's Lab., Torrent Pharma, and Morepen Labs. Average management risk is present at Gufic BioScience, while Below Average management risk is noted at Panacea Biotec. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average growth is seen at Gufic BioScience and Good growth at Morepen Labs. Below Average growth is reported for Divi's Lab., Torrent Pharma, RPG LifeScience., Advanced Enzyme, Guj. Themis Bio., and Panacea Biotec. Excellent capital structure is noted for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Gufic BioScience, RPG LifeScience., Morepen Labs., Advanced Enzyme, and Guj. Themis Bio., while Good capital structure is observed at Torrent Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Panacea Biotec at 269.46%, while the peer with the lowest is Advanced Enzyme at -14.22%. Gufic BioScience has a 1-year return of 16.75%, which is significantly lower than Panacea Biotec's return but higher than Advanced Enzyme's. Additionally, the peers with negative six-month returns include Gufic BioScience, Morepen Labs., Advanced Enzyme, and Guj. Themis Bio.

How big is Gufic BioScience?

As of 24th July, Gufic BioSciences Ltd has a market capitalization of 3,961.00 Cr, with net sales of 819.80 Cr and a net profit of 69.66 Cr reported in the latest four quarters.

As of 24th July, Gufic BioSciences Ltd has a market capitalization of 3,961.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Gufic BioSciences reported net sales of 819.80 Cr and a net profit of 69.66 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with shareholder's funds amounting to 532.56 Cr and total assets of 1,092.54 Cr.

When is the next results date for Gufic BioScience?

The next results date for Gufic BioScience is 13 August 2025.

The next results date for Gufic BioScience is scheduled for 13 August 2025.

How has been the historical performance of Gufic BioScience?

Gufic BioScience's historical performance for the fiscal year ending March 2025 shows increased net sales and improved cash flow, but decreased profitability with lower operating profit, profit before tax, and earnings per share compared to March 2024. Total assets and liabilities rose, indicating a stable financial position despite challenges in margins.

Answer:<BR>The historical performance of Gufic BioScience shows a mixed trend in its financial metrics for the fiscal year ending March 2025 compared to March 2024.<BR><BR>Breakdown:<BR>Gufic BioScience reported net sales of 819.81 Cr in March 2025, a slight increase from 806.67 Cr in March 2024. Total operating income also rose to 819.81 Cr from 806.67 Cr. However, total expenditure increased to 685.12 Cr from 660.79 Cr, leading to a decrease in operating profit (PBDIT) from 148.06 Cr to 138.32 Cr. Profit before tax fell to 94.14 Cr from 115.67 Cr, and profit after tax decreased to 69.65 Cr from 86.14 Cr, reflecting a decline in profitability. The earnings per share (EPS) also dropped from 8.59 to 6.94. On the balance sheet, total assets increased to 1,169.36 Cr from 1,092.54 Cr, while total liabilities rose to 1,169.36 Cr from 1,092.54 Cr, indicating a stable financial position. Cash flow from operating activities improved significantly to 122.00 Cr from a negative 7.00 Cr, contributing to a net cash inflow of 14.00 Cr compared to an outflow of 27.00 Cr in the previous year. Overall, while Gufic BioScience experienced growth in sales and cash flow from operations, it faced challenges in profitability and margins.

Are Gufic BioScience latest results good or bad?

Gufic BioScience's latest results are largely negative, with a 22.74% decline in net profit despite a 16.10% increase in revenue. Rising costs and shrinking operating margins raise concerns about future performance.

Gufic BioScience's latest results present a mixed picture, but overall, they lean towards the negative side. In Q2 FY26, the company reported a net profit of ₹16.82 crores, which is a significant decline of 22.74% year-on-year. This decline in profitability is concerning, especially given that the company's revenue grew by 16.10% year-on-year, reaching ₹237.05 crores, marking its highest quarterly sales ever.<BR><BR>While the revenue growth is a positive sign, it is overshadowed by the sharp drop in net profit and the contraction in operating margins, which fell to 15.96%, down 295 basis points from the previous year. Additionally, interest costs nearly doubled to ₹9.58 crores, consuming a substantial portion of operating profits and further impacting the bottom line.<BR><BR>The company's financial metrics indicate that it is facing significant challenges, particularly with rising costs and diminishing profitability. The overall outlook suggests caution, as the combination of declining margins and increasing debt servicing costs raises concerns about future performance. Therefore, while there are some positive aspects in terms of revenue growth, the deterioration in profitability and rising financial pressures suggest that the latest results are not favorable.

Should I buy, sell or hold Gufic BioScience?

Is Gufic BioScience technically bullish or bearish?

As of November 21, 2025, Gufic BioScience's trend is mildly bearish, indicated by bearish MACD and moving averages, while On-Balance Volume shows some bullish activity, suggesting mixed market sentiment.

As of 21 November 2025, the technical trend for Gufic BioScience has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by several indicators. The MACD is bearish on the weekly chart and mildly bearish on the monthly chart, while the Bollinger Bands also reflect a mildly bearish sentiment in both time frames. Moving averages indicate a mildly bearish trend on the daily chart. KST is bearish weekly and mildly bearish monthly, and Dow Theory supports a mildly bearish outlook across both time frames. However, the On-Balance Volume (OBV) shows bullish signals on both weekly and monthly charts, indicating some buying pressure. Overall, the combination of these indicators suggests a mildly bearish sentiment with some underlying bullish activity.

Is Gufic BioScience overvalued or undervalued?

As of December 3, 2025, Gufic BioScience is overvalued with a PE ratio of 61.64 and a Price to Book Value of 5.56, significantly higher than its peers, indicating that its current price of 349.85 is not justified given its low ROE of 9.02% and recent stock performance.

As of 3 December 2025, Gufic BioScience has moved from an expensive to a very expensive valuation grade. The company is currently overvalued, with a PE ratio of 61.64, a Price to Book Value of 5.56, and an EV to EBITDA of 28.83. In comparison to its peers, Sun Pharma has a PE ratio of 37.51 and an EV to EBITDA of 24.8, while Divi's Lab shows a PE ratio of 68.92, indicating that Gufic's valuation is significantly higher than some competitors.<BR><BR>Despite a recent stock return of -22.78% year-to-date compared to the Sensex's 8.92%, the valuation metrics suggest that Gufic BioScience is not justified at its current price of 349.85, especially when considering its low ROE of 9.02% and a PEG ratio of 0.00. Overall, the company's financial ratios and peer comparisons reinforce the conclusion that Gufic BioScience is overvalued in the current market environment.

Which are the latest news on Gufic BioScience?

Why is Gufic BioScience falling/rising?

As of 16-Dec, Gufic BioSciences Ltd's stock price is rising to Rs 353.25, up 2.27%, but has underperformed year-to-date with a 22.03% decline. Despite recent gains, concerns about declining investor interest and profitability persist.

As of 16-Dec, Gufic BioSciences Ltd's stock price is rising, currently at Rs 353.25, reflecting an increase of Rs 7.85 or 2.27%. This upward movement is notable as the stock has outperformed its sector by 2.8% today and has gained after two consecutive days of decline. The stock reached an intraday high of Rs 353.25, indicating positive momentum.<BR><BR>In terms of performance over various periods, the stock has shown a significant increase of 11.65% over the past month, contrasting with the Sensex's modest gain of 0.14%. However, it is important to note that the stock has underperformed over the longer term, with a year-to-date decline of 22.03% compared to the Sensex's increase of 8.37%.<BR><BR>Despite the recent rise, there are underlying concerns. The stock has experienced a decrease in investor participation, with delivery volume falling by 24.49% against the five-day average. Additionally, while the company has a low debt-to-equity ratio of 0.46, its profitability metrics are troubling, with a significant decline in profit after tax (PAT) of 29.89% over the latest six months.<BR><BR>Overall, while Gufic BioSciences Ltd is currently experiencing a rise in stock price, this is juxtaposed with longer-term underperformance and declining investor interest, which may raise caution among investors.